Device Trial Radar · NCT07148323
HemoSphere Alta Study
Last checked: Nov 20, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Oct 14, 2025
Primary completion
Nov 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Becton, Dickinson and CompanyPublic (BDX)
- Sponsor type
- Industry
- First posted
- Aug 29, 2025
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A prospective, non-randomized single arm study using the HemoSphere Alta Advanced Monitoring Platform and associated devices in adult subjects. Data collected from enrolled study subjects will be used for continual device development purposes.
Conditions
- Hemodynamic Instability
Interventions
HemoSphere Alta Monitor, Swan-Ganz IQ pulmonary arterial catheter, ForeSight IQ Large sensor, and Acumen IQ sensorDevice
Subjects with planned monitoring with a pulmonary artery catheter in the operating room, will be monitored with the above listed devices.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Data Collection using HemoSphere Alta Advanced Monitoring Platform and associated devicesTime frame: Up to 72 hours of device data collection during surgery and ICU
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Rochester Medical Center
Rochester, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.